Surfing the NASH Tsunami
Surfing the NASH Tsunami

Surfing the NASH Tsunami

      |      

Prenumeranter

   Senaste videorna

S4-E41.5 - Veronica Miller on “why are we validating a surrogate with a surrogate?”
15:20
S4-E41.4 - NITs to Qualify Patients for Trials vs to Evaluate Efficacy of Drugs
11:29
S4-E41.3 - Laurent Castera on the FDA's NIT Workshop
14:15
S4-E41.2 - Naim Alkhouri on clinical trial populations and the future decisions of FDA
15:09
S4-E41.1 - Naim Alkhouri on an NIT-based alternative path to conditional approval
13:29
S4-E40.5 - Paris NASH Review: More Topics and Final Thoughts
13:27
S4-E40.2 - Deeper Dive into the Landscape of NITs
08:59
S4-E40.1 - Liver as a Regenerative Organ and the Use and Limitations of NITs
11:13
S4-E40 - Review of Paris NASH 2023
52:57
S4-E39.4 - MASEF: Where will we be in 2 years?
09:37
S4-E39.3 - MASEF: Next Steps and New Cohorts
10:51
S4-E39.2 - MASEF: Cost Effectiveness and Application Settings
13:26
S4-E39.1 - MASEF: Study Parameters and Notable Results
11:47
S4-E39 - The Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF)
46:33
S4-E37.4 - NASH Patient Care: The Value of Patient Education
21:31
S4-E37.3 - NASH Patient Education: Liver Nurses’ Roles
13:06
S4-E37.2 - NASH Patient Support: Liver Nursing Challenges
15:14
S4-E37.1 - NASH Patient Support: Meet Today’s Liver Nurses
19:11
S4-E37 - Focus on the Role of Allied Health and Strengthening NASH Education
01:11:37
S4-E36.6 - From the Vault: NASH Challenges: Early Diagnosis & NASH Patient Management
15:03
Visa mer